Jiangsu Tasly Diyi Pharmaceutical Co., Ltd, awholly-owned subsidiary of Tianjin Tasly Group, is located in Tasly Huai’an BiologicalPharmaceuticals Park of Qingpu Industrial Park, Huai’an, Jiangsu. The site areais about 215333.3m2. At present, the first phase of manufacturingsite construction project, consisted of a chemical API manufacturing platformof 300 tons annual production capacity, a drug product (includingantineoplastic drug) manufacturing platform of about 2.2 billion tablets(granules) annual production capacity and an R&D and industrializationplatform, has been finished. In phase II and phase III construction phase, the solidpreparation manufacturing platform with core technologies of sustained-releaseand controlled-release, high-level injection manufacturing platform and tinnedpuerh tea manufacturing platform will be built.
As an importantcomponent of the health industry of Tasly Group, Jiangsu Tasly DiyiPharmaceutical Co., Ltd. is the core enterprise of chemical drug manufacturingof Tasly Group, has been honored as NationalNew-and-high-tech Enterprise, Post-doctoralProgram Station, ProvincialManagement Innovation Advanced Enterprise, Provincial Technology-based SME, Provincial Anti-brain tumor Drug Research Center and Huai’an City New Drug Preparation ResearchInstitute, and possesses province-level technology center and engineeringcenter.
The main productsof Tasly Diyi are chemical APIs and oral solid drug products, consisted ofproduct series of anti-tumor drugs, cardiovascular drugs, psychotropic drugsand liver drugs, etc. The company manufactures 12 APIs, including Temozolomide,Flutamide, Nicorandil, Sulpirde, Silibinin, Bezafibrate, etc. Oral solid drugproducts, mainly in forms of tablets and capsules, include more than 80 drug products,such as antiviral drug Adefovir Dipivoxil of first grade new drug, glioma drugTemozolomide Capsules of second grade new drug, prostatic cancer drugFlutamide Capsules/Tablets of second new drug, insomnia drugEszopiclone Tablets of second grade new drug and antihypertensive drugLisinopril Capsules of fourth grade new drug.
All drug productsmanufactured by the company have passed GMP certification 2010 version. Tabletsand capsules have passed TGA–GMP certification. API Sulpiride has passed EU-GMPcertification. And Adefovir Dipivoxil has been certified by KFDA. Tasly Diyi hasalso passed ISO 14001 EnvironmentManagement System certification, ISO9001 Quality Management Systemcertification, ISO 22000 Food Safety Management System certification,OHSAS18001 Occupational Health and Safety Advisory Services certification, etc.
Through a decade of effort, Tasly Diyibecomes one of key pharmaceutical enterprises of Jiangsu Province, and theleader of pharmaceutical industry of Huai’an City. Based on technologicalinnovation, Tasly Diyi has entered in its rapid developing period, where itssales and profits have both increased by more than 30% in last 3 successive years.In 2012 the sales reached 620,000,000RMB, of which the profit and the tax wereboth more than 1 hundred million.
With the requirement of “New factory, Newstandard, New atmosphere” and the goal of “Top-level factory, Top-level team,Top-level management, Top-level product”, Tasly Diyi persists in innovation,optimization of the product structure, and satisfaction of market demand, forthe purpose of driving the company to realizing a new development, turning anew page of Tasly Diyi in Huai’an this active and warm land, and contributingto building a rich, beautiful and happy New Huai’an.